Cetuximab in combination with oxaliplatin/5-fluorouracil (5FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer: An international phase II study.

Rubio, ED; Humblet, Yves; Tabernero, J.; Van Cutsem, E.; Cervantes, A.; André, Thibaut; Soulie, P; Corretge, S; Kisker, O.; de Gramont, A.

doi:10.1200/JCO.2005.09.112

Cetuximab in combination with oxaliplatin/5-fluorouracil (5FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer: An international phase II study.

Rubio, ED

;

Humblet, Yves

;

Tabernero, J.

;

Van Cutsem, E.

;

de Gramont, A.

;et.al.

(2005) 41st Annual Meeting of the American-Society-of-Clinical-Oncology — Location: Orlando (Fl) (13.May.2005)

Files

No attached file found for this publication.

Details

Authors

Rubio, ED
Author
Humblet, YvesUCLouvain
Author
Tabernero, J.
Author
Van Cutsem, E.
Author
André, ThibautUCLouvain
Author
de Gramont, A.
Author

Affiliations

Citations

APA
Chicago
FWB

Rubio, E., Humblet, Y., Tabernero, J., Van Cutsem, E., Cervantes, A., André, T., Soulie, P., Corretge, S., Kisker, O., & de Gramont, A. (2005). Cetuximab in combination with oxaliplatin/5-fluorouracil (5FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer: An international phase II study. Journal of Clinical Oncology, 23(16), 254S-254S. https://doi.org/10.1200/JCO.2005.09.112 (Original work published 2005)